FDA Clears The Pathwork(R) Tissue Of Origin Test For Hard-To-Identify Tumors

�Pathwork Diagnostics, Inc., a molecular nosology company focussed on oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Pathwork� Tissue of Origin Test for manipulation in determining the origin of unsettled tumors. The test analyzes a tumor's gene